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Abstract 
 
Aims 
To characterise the incidence of type 2 diabetes in the UK over the previous 20 years; and 
determine if there has been an increase in people aged 40 years or less at diagnosis. 
 
Methods 
For this retrospective cohort study, patients newly diagnosed with type 2 diabetes between 
1991 and 2010 were identified from the UK General Practice Research Database (CPRD). 
Patients were grouped into five-year intervals by year of diagnosis and age at diagnosis. A 
standardised incidence ratio (SIR) was determined (1991–1995=100). The percentage of 
newly diagnosed patients for each age group and aged ≤40 years was calculated for each 
five-year calendar period. The incidence rate by age and five-year calendar period was also 
determined. 
 
Results  
The overall SIR increased to 158 (95%CI 157–160, p<0.001), 237 (235–238, p<0.001) and 275 
(273–276, p<0.001) for 1996–2000, 2001–2005 and 2006–2010, respectively. For those ≤40, 
the respective values were 217(209–226, p<0.001), 327 (320–335, p<0.001) and 598 (589–
608, p<0.001). An increase in incidence occurred with increasing five-year calendar period. 
The incidence of type 2 diabetes was higher for males after the age of 40 and higher for 
females aged ≤40. The percentage of patients aged ≤40 years at diagnosis increased with 
each increasing five-year calendar period (5.9%, 8.4%, 8.5% and 12.4%, respectively). 
 
Conclusions  
There was a significant increase in the incidence of diagnosed type 2 diabetes between 1991 
and 2010 and the proportion of people diagnosed at an earlier age has increased markedly. 
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Introduction 
The incidence and prevalence of type 2 diabetes has been increasing in the UK.1 Although 
the cause of type 2 diabetes is multi-factorial, it is largely related to obesity and physical 
inactivity.2 There has been an increase in the prevalence of type 2 diabetes in children and 
adolescents, which is thought to be dependent on many factors such as obesity, diet, family 
history of diabetes, ethnicity, sedentary lifestyle, puberty, low birth weight and exposure to 
diabetes in utero.3,4,5,6,7  
Studies in the UK secondary care population and the US have shown that the age of 
diagnosis of type 2 diabetes has decreased over time.8,9 Early onset type 2 diabetes will 
result in afflicted people living a larger proportion of their lives exposed to the toxicity of 
dysglycaemia, such that their complications could conceivably more reflect those of people 
with type 1 diabetes; for example, increased rates of microvascular complications. The onset 
of type 2 diabetes prior to the age of 45 is an independent risk factor in the development of 
retinopathy after matching on diabetes duration and adjusting for traditional risk factors 
such as glycaemic control and hypertension.10  In addition, youth onset type 2 diabetes in 
Pima Indians aged less than 20 years at diagnosis was associated with an increased incidence 
of end stage renal disease and mortality in middle age compared with older onset 
diabetes.11 In terms of cardiovascular risk, early onset type 2 diabetes may constitute a more 
aggressive disease.12 ,13   
This study aimed to characterise the incidence of diabetes over the past 20 years in the 
United Kingdom. We also aimed to determine if there was an increase in the proportion of 
people diagnosed with diabetes who were young. 
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Methods  
Data source 
Patients with type 2 diabetes were identified in the Clinical Practice Research Datalink 
(CPRD).14 CPRD contains clinically rich data that are collected in a non-interventional way 
from the daily record-keeping of primary care physicians in the UK. These pseudonymised 
data include patient demographics and medical history, including diagnoses, test results and 
prescriptions. The data extract used for this study comprised records up to June 2011 and 
contained 143 million patient years of computerised data of acceptable quality for research 
purposes. CPRD checks the data to ensure it is of an acceptable standard and over 550 peer 
reviewed studies using CPRD have been published.15 Ethical approval for this study by the 
CPRD Independent Scientific Advisory Committee was granted on 23/02/2012, protocol 
number 12_019R. 
 
Selection criteria 
Included patients had to be newly diagnosed with type 2 diabetes between 1991 and 2010, 
inclusively. Patients were attributed a diagnosis of type 2 diabetes if they met one of the 
following criteria: 
1. A diagnosis of type 2 diabetes and a prescription for a glucose lowering medicine 
excluding insulin 
2. Diagnoses for type 1 or type 2 diabetes or diabetes where type not specified and 
prescriptions for more than one type of glucose-lowering medicine excluding insulin 
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3. A diagnosis of type 2 diabetes, no diagnosis of type 1 diabetes, no prescription for 
exogenous insulin or a glucose-lowering medicine other than insulin 
4. A diagnosis of type 2 diabetes, no diagnosis of type 1 diabetes, a prescription for a 
glucose-lowering medicine but no prescription for insulin 
5. A prescription for glucose biosensor strips and a medication(s) used for diabetes but no 
diagnosis of diabetes and no prescription for insulin 
6. A diagnosis for type 2 diabetes, a diagnosis of type 1 diabetes but no prescription for  
insulin 
7. A diagnosis of diabetes (type not specified) but no prescription for insulin. 
Criteria 1, 3 and 4 include no conflicting diagnoses. Criteria 2 uses conflicting diagnoses but 
is based on the assumption that the use of at least two different OHAs confirms the type 2 
diagnosis. Criteria 5, 6 and 7 are included as patients not treated with insulin cannot have 
type 1 diabetes. 
 
Type 2 diabetes incidence 
The incident date of diabetes was taken as the earliest of either the date of diagnosis of 
diabetes or the date of the first diabetes-related prescription (glucose biosensor strip, OHA 
or insulin). Cases also had a minimum ‘wash-in’ period of one year between the incident 
date and the latest of the patient registration date and practice up-to-standard date. 
Patient data were categorised into five-year intervals by year of diagnosis and age at 
diagnosis. The percentage of all newly diagnosed patients in each age group was calculated 
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by dividing the number of patients diagnosed in each age group per five-year calendar 
period by the total number of patients diagnosed in the same relevant five-year calendar 
period. The percentage of patients aged ≤40 years at diagnosis was calculated in a similar 
way. Incidence rates were calculated yearly and by age group and five-year calendar period 
by dividing the number of incident cases by the number of person-years in CPRD for the 
same calendar year and age group where applicable. Patients were included in the person-
years estimate (denominator) from one year following the latest of the up-to-standard date 
or the practice date until the earliest of their death date, date transferred out of practice or 
incident date of diabetes (patients need not necessarily have had contact with their general 
practice to be included). Incidence was compared within age groups over time by calculating 
an age-and-sex-stratified standardised incidence ratio (SIR), akin to a standardised mortality 
rate (SMR). 
 
Statistical methods 
Changes in SIRs were compared by means of the Byar approximation Poisson method. 
Statistical analyses were carried out using SPSS-18 and R16. Baseline characteristics were 
compared between five-year calendar periods using Mantel-Haenszel linear-by-linear chi-
squared test for categorical variables and one-way ANOVA or Kruskall-Wallis test for 
continuous variables, depending on their distribution. Levene’s test was employed to test for 
homogeneity of variances. If the assumption of homogeneity of variances had been violated 
and group sizes were unequal, Welch's F was used. Differences between five-year calendar 
periods were explored using Games-Howell procedure, which can be used when population 
variances and sample sizes differ. Kendall’s tau-b was used to determine if there was a 
significant association between percentage diagnosed and five-year calendar period. 
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Confidence intervals for incidence rates were calculated using the Byar approximation 
method and for proportions using mid-P confidence interval adaptation of the Clopper-
Pearson interval. 
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Results 
Baseline characteristics 
Baseline characteristics by year and age group at diagnosis are detailed in Table 1. In each 
five-year calendar period, slightly more newly diagnosed patients were female than male. 
For people aged ≤40 at diagnosis, body mass index (BMI) changed from a mean (SD) of 32.2 
kg/m2 (7.7 kg/m2) in 1991–1995 to 29.2 kg/m2 (5.3 kg/m2) in 1996-2000 (p=0.649), 32.6 
kg/m2 (7.7 kg/m2) in 2001–2005 (p=0.003) and 30.8 kg/m2 (6.1kg/m2) in 2006-2010 
(p<0.001). For people >40 at diagnosis, mean BMI increased with each successive five-year 
calendar period from a mean of 29.2 kg/m2 (5.3 kg/m2) in 1991–1995 to 30.8 kg/m2 (6.1 
kg/m2) in 2006–2010 (p<0.001). 
For patients aged ≤40 years at diagnosis, mean (SD) glycated haemoglobin (HbA1c) at 
baseline was 8.3% (3.0%) in 1991–1995, decreasing to 6.1% (2.2%) in 1996–2000 (p<0.001) 
before increasing to 6.7% (2.5%) in 2001–2005 (p<0.001) and 7.4% (2.6%) in 2006–2010 
(p<0.001). For patients aged >40 years at diagnosis HbA1c was 9.0% (2.9%) in 1991–1995, 
decreasing to 7.6% (2.6%) in 1996–2000 (p<0.001), 7.5% (2.3%) in 2001–2005 (p<0.001) and 
7.5% (2.2%) in 2006–2010 (p=0.776). Mean systolic and diastolic blood pressure and total 
cholesterol levels decreased in each five-year calendar period between 1991 and 2010 for 
patients aged >40 at diagnosis. For patients ≤40 at diagnosis, systolic and diastolic blood 
pressure and total cholesterol were lower in 2006-2010 than any other year. The number of 
GP contacts—an indicator of general morbidity—in the year prior to diagnosis of type 2 
diabetes increased during the study period from a median (IQR) of 5.0 (2.0-9.0) and 6.0 (3.0-
11.0) contacts in 1991–1995 to 7.0 (3.0-12.0; p<0.001) and 8.0 (4.0-15.0; p<0.001) contacts 
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in 2006–2010 for patients aged ≤40 and >40 at diagnosis, respectively. The time to first drug 
treatment for type 2 diabetes following diagnosis decreased from a median (IQR) of 0.4 (0.0-
3.2) and 0.5 (0.0-3.1) years in 1991–1995 to 0.0 (0.0-0.3; p<0.001) and 0.1 (0.0-0.6; p<0.001) 
years in 2006–2010 for patients aged ≤40 and >40 at diagnosis, respectively. There was no 
change in the median score for the Charlson morbidity index during the study period for 
patients aged ≤40 years at diagnosis and decreased from 4.0 (3.0-5.0) in 1991-1995 to 3.0 
(2.0-5.0) in 1996-2000, 2001-2005 and 2006-2010 for patients aged >40 at diagnosis. More 
patients had suffered from conditions that could be associated with a complication of 
diabetes prior to their diagnosis of type 2 diabetes in increasing five-year calendar periods 
and there was a significant difference between groups for coronary heart disease (CHD) 
(p<0.001), cerebrovascular disease (CVD) (p<0.001), diabetic foot and peripheral vascular 
disease (PVD) (p<0.001), eye-related complications (p<0.001) and end stage renal disease 
(ESRD) (p<0.001) for patients aged >40 at diagnosis.  
 
Standardised incidence ratio 
The SIR increased within each five-year calendar period from 1991–1995 (SIR=100) to 158 (CI 
157–160, p<0.001), 237 (235–238, p<0.001) and 275 (273–276, p<0.001), respectively (Table 
2). For those aged 40 years and under, the respective SIRs were 217 (209–226, p<0.001), 327 
(32017–335, p<0.001) and 598 (589–608, p<0.001; Table 3). 
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Specific incidence rates 
The incidence of type 2 diabetes increased between 1991 and 2002 from 169 newly 
diagnosed people per 100,000 person-years (95%CI 160–178) to 448 (95%CI 442–455) 
before decreasing to 376 (95%CI 371–382) per 100,000 in 2006 (Figure 1). By 2009, the 
incidence of type 2 diabetes had increased to 533 (95%CI 526–539) per 100,000 before 
decreasing slightly to 515 (95%CI 509–521) per 100,000 in 2010. The incidence of type 2 
diabetes for males and females followed a similar pattern, but incidence was higher for 
males than for females. HbA1c levels at baseline were 9.3% (95%CI 8.5%-10.2%), 7.1% 
(95%CI 7.0%-7.1%), 7.7% (95%CI 7.6%-7.7%), 7.4% (95%CI 7.4%-7.4%) and 7.3% (95%CI 7.2%-
7.3%) in 1991, 2002, 2006, 2009 and 2010, respectively 
The incidence rate for type 2 diabetes increased with each increasing five-year calendar 
period for all age groups and for both genders, with the exception of females who were 90 
years and over, where the incidence rate fell to 482 from 452 people per 100,000 in the final 
two five-year calendar periods (Figure 2a and 2b). Overall, between 1996 and 2005, the 
incidence rate was highest in the 70–74 age group at 892 and 1,415 people per 100,000 for 
1996–2000 and 2001–2005, respectively. For 1991–1995, the incidence rate was highest in 
the 75–79 age group at 605 people per 100,000. In 2006-2010, the highest incidence rates 
were seen in the 70-74 and 75-79 age groups at 1486 per 100,000. After the age of 40 years, 
the incidence was higher in males for each five-year calendar period (Figure 2a and 2b). 
However, females had a higher incidence than did males for many of the age groups below 
40 years, including the age groups between 20 and 39 years for all five-year calendar 
periods. 
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A larger percentage of patients were diagnosed between 65 and 69 years of age between 
1991 and 2005 than any other age group. However, between 2006 and 2010, the most 
common age at diagnosis was lower, at 60–64 years. For males, the largest percentage of 
patients was diagnosed between 65 and 69 years of age from 2001–2005, but between 60 
and 64 years of age for 1991–1995, 1996–2000 and 2006–2010 (Figure 3a). The largest 
percentage of females was diagnosed between the ages of 70 to 74 years for 1991–2005 
(Figure 3c). This had decreased to 60–64 years of age between 2006 and 2010. 
The percentage of patients aged 40 years or less at diabetes diagnosis increased with each 
increasing five-year calendar period for males (Figure 3b) and increased between 1991-1995 
and 2006-2010 in females (figure 3d). However, there was no increase observed between 
1996-2000 and 2001-2010. Overall, the percentage of patients diagnosed on or before the 
age of 40 years was 5.9% (95%CI 5.5%-6.3%), 8.4% (95%CI 8.2%-8.7%), 8.5% (95%CI 8.3%-
8.6%) and 12.4% (95%CI 12.2%-12.5%) for 1991–1995, 1996–2000, 2001–2005 and 2006–
2010, respectively. There was a significant association between five-year calendar period 
and the number of patients diagnosed before and after the age of 40 (p<0.001). However, 
there were differences between the incidence in males and females, where the incidence 
was higher in females at earlier ages. 
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Discussion 
The incidence of diagnosed type 2 diabetes increased markedly between 1991 and 2010 in 
most age groups. Furthermore, the incidence rate increased with increasing age until 75 
years of age. Importantly, not only was the overall incidence increasing, the proportion of 
people who were aged 40 years or less at diagnosis increased markedly. 
The study results could reflect an increase in the incidence of type 2 diabetes in the UK 
population and a decrease in the age of onset. The incidence results are supported by 
incidence and prevalence rates previously demonstrated for the UK1, US17 and worldwide18. 
Conversely, between 2004 and 2006, the incidence of diabetes in Denmark has decreased 
slightly.19 The primary modifiable risk factor contributing to development of type 2 diabetes 
is energy balance as measured by BMI as a proxy for obesity. In the general UK population, 
both the prevalence and severity of obesity has been rising since 1993.20 Between 1993 and 
2010, the proportion of the UK population who were estimated to be obese increased from 
13% to 26% for men and 16% to 26% for women.15 For children, the prevalence of obesity 
has increased between 1995 and 2010 from 11% to 17% and from 12% to 15% for boys and 
girls, respectively.15 However, the percentage of adults meeting recommended levels for 
physical activity increased in the UK from 32% and 21% in 1997 to 42% and 31% in 2008 for 
men and women, respectively.15  There is an inverse relationship between BMI and age of 
onset of type 2 diabetes21 and intensive lifestyle intervention with a minimum of 7% weight 
loss and 150 minutes of physical activity per week reduced the incidence rate for diabetes by 
58%.22 A study based in Germany revealed that severe weight gain between the ages of 25 
and 40 was associated with a higher risk of diabetes than if weight was stable in early 
adulthood and increased in later life (1.5 and 4.3 times the risk for males and females, 
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respectively) and the age at diagnosis was also lowered (five and three years for males and 
females, respectively).23 For the study period, there was an increase in mean BMI at baseline 
for people diagnosed after the age of 40 for each successive five-year calendar period and 
both male and female weight increased in each five-year group during the study period. 
However, for people aged 40 years or less at diagnosis, the mean BMI fluctuated between 
five year calendar periods. A similar pattern was also observed for mean weight for both 
males and females in this age group. The decrease in 2006-2010 could be partly accounted 
for by the increased percentage of children and adolescents diagnosed in this five-year 
calendar period.  
The increase in the incidence of type 2 diabetes and the proportion of patients aged 40 years 
or less at diagnosis may be due, at least in part, to increased screening for type 2 diabetes. 
Unlike type 1 diabetes, the symptoms of type 2 diabetes are not always obvious and the 
condition can remain undiagnosed for many years. A study carried out between 1978 and 
1982 found that the actual onset of type 2 diabetes may be at least four to seven years 
before clinical diagnosis.24 Therefore, any increased screening for type 2 diabetes may have 
an impact on how early diagnosis is achieved after onset of the condition. In the last decade, 
changes to the General Medical Services and Pharmacy Contracts, the implementation of the 
National Diabetes Framework, and local initiatives have increased the awareness of 
diabetes.25,26 For example, the Quality and Outcomes Framework was introduced on 1st April 
2004.Error! Bookmark not defined. In addition, changes have been made to the criteria for diagnosing 
type 2 diabetes during the study period. In 2000, the WHO new diagnostic criteria for the 
diagnosis of diabetes was implemented in the UK, which included lowering the threshold for 
diagnosing diabetes by fasting plasma glucose from 7.8 mmol/l to 7.0 mmol/l.27 These 
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changes would have led to an increase in the number of patients diagnosed with type 2 
diabetes, a reduction in the number of patients with undiagnosed diabetes and a decrease in 
the age at diagnosis. If the increase in incidence is a result of increased screening, this could 
be viewed positively as patients will receive appropriate diabetes care at an earlier stage of 
their disease. In support of this theory of an ascertainment effect, HbA1c levels at baseline 
followed an inverse pattern when compared with annual incidence rates for type 2 diabetes. 
However, it is important to note that there was a large amount of missing data in the earlier 
years of the study period Blood pressure and total cholesterol decreased throughout the 
study period, which may be an indication of increased screening for type 2 diabetes in 
patients who are already treated for hypercholesterolaemia and hypertension. The 
increased use of statins is likely to account for the reduction in baseline cholesterol seen 
during the study period. There is some concern that statin use may increase the incidence of 
diabetes, but despite this uncertainty, the benefits of statins on cardiovascular disease 
outweigh any possible diabetes risk.28 During the study period, more diabetic complications 
have been recorded in relation to increasing five-year calendar periods. This could indicate a 
number of factors; for example, improved survival of patients with advanced disease, or 
patients suffering from more advanced disease at diagnosis. Improved recording of 
diagnoses in CPRD could also account for this trend. 
Irrespective of the cause, the results of this study show that type 2 diabetes is common 
under the age of 40 years. Early onset type 2 diabetes could result in longer disease duration 
and lead to an increased risk of developing diabetic complications. This is likely to place an 
increasing burden on healthcare resources, and increased patient morbidity may lead to a 
poorer quality of life. An earlier age of onset of type 2 diabetes may also lead to mortality 
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occurring at a younger age. The Framingham Heart Study showed that the risk of CHD and 
CHD-related death increased with increasing duration of diabetes.29 The Northern 
Manhattan Study found that diabetes duration was independently associated with an 
increased risk of ischaemic stroke.30 In addition, youth onset type 2 diabetes has been linked 
to an increased risk of developing diabetic complications including cardiovascular disease 
and retinopathy.8,13,12 The Vascular Risk Assessment and Management Programme called 
NHS Health Check has been gradually introduced in England for everyone aged 40 to 74.31 
However, it is important to consider if screening programmes should include patients under 
the age of 40 as earlier diagnosis will lead to the earlier initiation of appropriate diabetes 
care and treatment. Conversely, the results from the ADDITION-Cambridge trial 
demonstrated that screening people aged 40-69 at high risk of having undiagnosed diabetes 
was not associated with a reduction in all-cause, cardiovascular-related or diabetes-related 
mortality within 10 years.32 
As already discussed, the main limitation of this study is the use of age of diagnosis to 
understand any trends in the age of onset of type 2 diabetes. In addition, the recording of 
measurements such as weight, BMI, total cholesterol, smoking status and BP improved 
during the study period. For BMI, the percentage of patients with a recorded BMI increased 
from 38% in 1991–1995 to 46% in 2006–2010 for those patients aged 40 years or less at 
diagnosis and this may be skewed as overweight patients are more likely to have their 
weight measured. Medical conditions like type 2 diabetes may be better recorded in CPRD in 
more recent years and this could have contributed to the increase in incidence rate over 
time. In addition, a consensus statement recommending the use of a DCCT-aligned Hba1c 
method in the UK was not published until 2000 and HbA1c levels in the early period may not 
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have been standardised throughout the UK.33 Therefore, comparisons of mean HbA1c levels 
between five-year calendar periods should be interpreted with caution. One other study 
limitation concerns the allocation of a diagnosis of type 2 diabetes to patients in CPRD: in 
particular, the coding of diabetes may have changed in recent years. The term ‘insulin-
dependent diabetes mellitus’ (IDDM) was used more commonly in earlier years, whereas 
‘type 1 diabetes’ is now more frequently used. Some people with type 2 diabetes and 
receiving prescriptions for insulin may have been attributed a code for IDDM, leading to 
diabetes type being misclassified; this may exaggerate any increase in incidence seen during 
the study period. In addition, the criteria used in this study to attribute a diagnosis of type 2 
diabetes to CPRD patients did not utilise BMI or laboratory data, which may have improved 
the classification of diabetes type.34 Age was not used to classify diabetes type in this study 
as we were specifically investigating the proportion of people with type 2 diabetes in 
younger age groups. 
The incidence of diagnosed type 2 diabetes has increased markedly and consistently. The 
proportion of very early onset type 2 diabetes continues to increase as a proportion of those 
diagnosed and these people have a greater opportunity to develop long-term complications. 
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Table 1.  Baseline characteristics for patients diagnosed with type 2 diabetes before and after 40 years of age 
Parameter 1991–1995 1996–2000 2001–2005 2006–2010 p-value 
≤40 >40 ≤40 >40 ≤40 >40 ≤40 >40 ≤40 >40 
N 642 10241 2752 29846 7519 81324 15326 108621    
Males (%) 312 (49%) 5,404 (53%) 1,233 (45%) 15,613 (52%) 3,397 (45%) 42,452 (52%) 6,546 (43%) 56,925 (52%) <0.001 0.987 
Age (years), mean (SD) 32.5 (7.4) 66.0 (11.8) 30.9 (8.6) 65.3 (12.1) 31.1 (8.5) 65.1 (12.1) 29.4 (9.4) 64.2 (12.6) <0.001 <0.001 
Smoking status:             0.159 <0.001 
n (%) 438 (68%) 7,016 (69%) 2,094 (76%) 25,329 (85%) 6,154 (82%) 74,601 (92%) 13,477 (88%) 106,938 (98%)    
Non-smoker, n (%) 266 (61%) 4,320 (62%) 1,185 (57%) 13,835 (55%) 3,195 (52%) 33,704 (45%) 7,069 (52%) 44,701 (42%)    
Ex-smoker, n (%) 49 (11%) 1,174 (17%) 206 (10%) 5,859 (23%) 889 (14%) 25,664 (34%) 2,639 (20%) 43,431 (41%)    
Current smoker, n (%) 123 (28%) 1,522 (22%) 703 (34%) 5,635 (22%) 2,070 (34%) 15,233 (20%) 3,769 (28) 18,806 (18%)    
HbA1c (%)             <0.001 <0.001 
n (%) 57 (9%) 973 (10%) 1,327 (48%) 10,941 (37%) 3,879 (52%) 41,732 (51%) 4,372 (29%) 51,103 (47%)    
mean (SD) 8.3 (3.0) 9.0 (2.9) 6.1 (2.2) 7.6 (2.6) 6.7 (2.5) 7.5 (2.3) 7.4 (2.6) 7.5 (2.2)    
BMI (kg/m2)             <0.001 <0.001 
n (%) 244 (38%) 4,367 (43%) 888 (32%) 12,836 (43%) 3,275 (44%) 46,774 (58%) 7,103 (46%) 70,298 (65%)    
mean (SD) 32.2 (7.7) 29.2 (5.3) 31.6 (7.6) 29.9 (5.7) 32.6 (7.7) 30.5 (5.8) 30.8 (8.0) 30.8 (6.1)    
Weight: males (kg)             <0.001 <0.001 
n (%) 128 (41%) 2,511 (46) 437 (35%) 7,265 (47%) 1,559 (46%) 25,624 (60%) 3,080 (47%) 38,687 (68%)    
mean (SD) 95.8 (22.5) 86.5 (15.8) 97.5 (25.6) 89.5 (17.1) 100.1 (26.7) 91.7 (17.7) 96.3 (28.3) 93.6 (18.9)    
Weight: females (kg)             <0.001 <0.001 
n (%) 120 (36%) 2,040 (42%) 505 (33%) 6,021 (42%) 1,839 (45%) 21,914 (56%) 4,312 (49%) 32,269 (62%)    
mean (SD) 86.3 (22.3) 76.1 (16.3) 83.2 (22.8) 77.7 (17.5) 87.4 (23.8) 79.2 (17.8) 80.3 (24.6) 79.7 (18.8)    
Time to first treatment (years):             <0.001 <0.001  
mean (SD) 2.2 (3.4) 2.0 (3.0) 1.7 (2.5) 1.7 (2.4) 1.0 (1.7) 1.4 (2.0) 0.3 (0.7) 0.5 (0.9)    
median (IQR) 0.4 (0.0-3.2) 0.5 (0.0-3.1) 0.4 (0.0-2.4) 0.5 (0.0-2.6) 0.1 (0.0-1.2) 0.4 (0.0-2.3) 0.0 (0.0-0.3) 0.1 (0.0-0.6)    
Blood pressure                
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n (%) 309 (48%) 6,241 (61%) 1,335 (49%) 19,765 (66%) 4,543 (60%) 68,199 (84%) 8,962 (58%) 93,307 (86%)    
Diastolic BP, mean (SD) 82.7 (11.1) 85.3 (10.9) 80.7 (12.3) 84.4 (10.7) 81.5 (12.1) 82.5 (11.0) 78.6 (11.8) 80.1 (10.8) <0.001 <0.001 
Systolic BP, mean (SD) 132 (19) 150 (21) 128 (19) 148 (20) 130 (18) 144 (19) 125 (17) 138 (18) <0.001 <0.001 
Number of GP contacts:             <0.001 <0.001 
mean (SD) 7.0 (6.5) 8.0 (7.3) 7.2 (7.4) 9.0 (8.3 7.3 (7.8) 9.1 (9.0) 9.1 (9.6) 10.9 (11.0)    
median (IQR) 5.0 (2.0-9.0) 6.0 (3.0-11.0) 5.0 (2.0-10.0) 7.0 (3.0-12.0) 5.0 (2.0-10.0) 7.0 (3.0-12.0) 7.0 (3.0-12.0) 8.0 (4.0-15.0)    
Total chol (mmol/l)             <0.001 <0.001 
n (%) 69 (11%) 1,250 (12%) 556 (20%) 9,581 (32%) 2,832 (38%) 54,182 (67%) 5,086 (33%) 82,459 (76%)    
mean (SD) 6.0 (1.3) 6.2 (1.2) 5.5 (1.2) 5.8 (1.2) 5.4 (1.2) 5.5 (1.2) 5.3 (1.2) 5.1 (1.2)    
Charlson Index:             <0.001 <0.001 
mean (SD) 1.2 (0.8) 1.7 (1.2) 0.8 (0.8) 1.5 (1.3) 0.8 (0.9) 1.5 (1.3) 1.1 (0.8) 1.8 (1.5)    
median (IQR) 1.0 (1.0-1.0) 1.0 (1.0-2.0) 1.0 (0.0-1.0) 1.0 (1.0-2.0) 1.0 (0.0-1.0) 1.0 (1.0-2.0) 1.0 (1.0-1.0) 1.0 (1.0-3.0)    
Adjusted Charlson Index:             <0.001 <0.001 
mean (SD) 1.2 (0.8) 3.8 (2.0) 0.8 (0.8) 3.3 (2.2) 0.8 (0.9) 3.3 (2.3) 1.1 (0.8) 3.6 (2.5)    
median (IQR) 1.0 (1.0-1.0) 4.0 (3.0-5.0) 1.0 (0.0-1.0) 3.0 (2.0-5.0) 1.0 (0.0-1.0) 3.0 (2.0-5.0) 1.0 (1.0-1.0) 3.0 (2.0-5.0)    
Diabetic complications:                
CHD (%) 0 (0.0%) 0 (0.0%) 9 (0.0%) 1011 (3.0%) 49 (1.0%) 5,738 (7.0%) 83 (1.0%) 9,626 (9%) 0.147 <0.001 
CVD (%) 0 (0.0%) 0 (0.0%) 1 (0.0%) 324 (1.0%) 14 (0.0%) 1,638 (2.0%) 42 (0.0%) 2,884 (3%) 0.005 <0.001 
Diabetic foot and PVD (%) 0 (0.0%) 0 (0.0%) 1 (0.0%) 138 (0.0%) 3 (0.0%) 638 (1.0%) 7 (0.0%) 956 (1%) 0.622 <0.001 
Eye-related complications (%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0.849 <0.001 
ESRD (%) 0 (0.0%) 0 (0.0%) 3 (0.0%) 109 (0.0%) 33 (0.0%) 657 (1.0%) 134 (1.0%) 1,756 (2.0%) <0.001 <0.001 
Smoking status was the nearest status recorded prior to the index date. For BMI, HbA1c, weight, blood pressure (BP), total cholesterol the nearest record to the index date was taken, 
provided it was no more than 365 days prior to or 30 days after the index date. The number of GP contacts represents the number of GP contacts in the year prior to the index date. Diabetic 
complications refer to whether patient had record of  a diabetic complication prior to index date. 
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Table 2. Standardised incidence ratio (SIR: 1991–1995=100) for five-yearly periods to 2010. 
Year group Observed Expected SIR 95% CI p 
All subjects       
1991–1995 10,883 n/a 100    
1996–2000 32,596 20,601 158 157 160 <0.001 
2001–2005 88,835 37,545 237 235 238 <0.001 
2006–2010 87,970 45,135 275 273 276 <0.001 
Males       
1991–1995 5,716 n/a 100    
1996–2000 16,846 10,945 154 152 156 <0.001 
2001–2005 45,849 20,209 227 225 229 <0.001 
2006–2010 63,471 24,499 259 257 261 <0.001 
Females       
1991–1995 5,167 n/a 100    
1996–2000 15,750 9,656 163 161 166 <0.001 
2001–2005 42,986 17,336 248 246 250 <0.001 
2006–2010 60,461 20,636 293 291 295 <0.001 
Under 40 years       
1991–1995 577 n/a 100    
1996–2000 2,496 1,148 217 209 226 <0.001 
2001–2005 6,798 2,077 327 320 335 <0.001 
2006–2010 14,073 2,352 598 589 608 <0.001 
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Figure 1. Incidence of type 2 diabetes per 100,000 population by year 
 
 
1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 
HbA1c 9.32 9.39 8.97 9.22 8.66 8.45 7.73 7.45 7.47 7.19 7.08 7.06 7.51 7.71 7.65 7.67 7.58 7.56 7.39 7.26 
Male 183 186 187 173 200 201 220 265 292 387 455 472 401 413 397 400 468 508 553 536 
Female 156 158 153 152 177 180 195 231 263 347 407 426 361 370 358 354 418 459 514 495 
Overall 169 172 170 162 188 190 207 248 277 366 430 448 380 391 377 376 442 483 533 515 
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Figure 2.  Incidence of new cases of type 2 diabetes per 100,000 population by year 
 
 
 
a) Males and b) females 
0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85-89 90+ 
1991-1995 2 2 2 7 6 14 27 53 107 182 278 423 578 619 619 681 645 453 360 
1996-2000 11 10 8 17 26 31 48 93 192 301 443 588 838 956 1013 974 827 704 420 
2001-2005 16 11 14 22 38 48 88 134 246 439 661 879 1170 1470 1560 1499 1258 1000 493 
2006-2010 40 32 32 52 60 89 136 209 329 516 770 992 1233 1486 1656 1625 1411 1189 538 
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Figure 3.  Percentage of new cases of type 2 diabetes between 1991 and 2010 by age group and calendar period 
  
  
a) Males, all ages, b) males diagnosed at or before 40 years of age, c) females, all ages, d) females diagnosed at or before 40 years of age 
White diamond = 1991–1995, grey square = 1996–2000, white triangle = 2001–2005, black circle = 2006–2010
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